<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chagas disease: Chronic Trypanosoma cruzi infection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chagas disease: Chronic Trypanosoma cruzi infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chagas disease: Chronic Trypanosoma cruzi infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Caryn Bern, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Antonio Marin-Neto, MD, PhD, FACC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 23, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H707610184"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chagas disease is caused by infection with the protozoan parasite <em>Trypanosoma cruzi</em>; the major chronic manifestations are Chagas cardiomyopathy and gastrointestinal disease [<a href="#rid1">1-6</a>].</p><p>Issues related to the natural history, clinical manifestations, diagnosis, and management of chronic Chagas disease will be reviewed here. Issues related to acute and congenital Chagas infection are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/114181.html" rel="external">"Chagas disease: Acute and congenital Trypanosoma cruzi infection"</a>.)</p><p>Issues related to the epidemiology and prevention of Chagas disease are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5698.html" rel="external">"Chagas disease: Epidemiology, screening, and prevention"</a>.)</p><p>Issues related to cardiac and gastrointestinal Chagas are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4955.html" rel="external">"Chronic Chagas cardiomyopathy: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4925.html" rel="external">"Chronic Chagas cardiomyopathy: Management and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/5700.html" rel="external">"Chagas gastrointestinal disease"</a>.)</p><p class="headingAnchor" id="H481275196"><span class="h1">NATURAL HISTORY</span></p><p class="headingAnchor" id="H2906167089"><span class="h2">Overview</span><span class="headingEndMark"> — </span><em>T. cruzi</em> infection is characterized by two phases, acute and chronic  (<a class="graphic graphic_figure graphicRef114565" href="/z/d/graphic/114565.html" rel="external">figure 1</a>). The acute phase lasts 8 to 12 weeks after transmission. (See  <a class="medical medical_review" href="/z/d/html/114181.html" rel="external">"Chagas disease: Acute and congenital Trypanosoma cruzi infection"</a>.)</p><p>When the host immune response succeeds in decreasing parasite replication, parasitemia falls below levels detectable by microscopy, acute symptoms resolve, and the patient passes into the chronic phase. In the absence of successful antitrypanosomal therapy, this usually occurs 8 to 12 weeks after the onset of infection, and the chronic phase lasts for the life of the patient. Nearly all <em>T. cruzi-</em>infected persons have the indeterminate (asymptomatic) form during the first one to three decades of the chronic phase; an estimated 20 to 40 percent will subsequently develop cardiac and/or gastrointestinal forms of the disease [<a href="#rid7">7</a>].</p><p>Individuals with chronic <em>T. cruzi</em> infection are capable of transmitting the parasite to the insect vector and to other humans via blood components, organ donation, or transplacentally, regardless of clinical manifestations [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/5698.html" rel="external">"Chagas disease: Epidemiology, screening, and prevention", section on 'Nonvectorial transmission'</a>.)</p><p class="headingAnchor" id="H771514762"><span class="h2">Indeterminate form</span><span class="headingEndMark"> — </span>Patients with the indeterminate form of the chronic phase of <em>T. cruzi</em> infection have positive serology but no symptoms or signs of cardiomyopathy or gastrointestinal disease, as described below. (See <a class="local">'Identify organ involvement'</a> below.)</p><p>The indeterminate form may persist for decades. About 20 to 30 percent with the indeterminate form develop cardiomyopathy after a latent period ranging from 5 to 30 years [<a href="#rid3">3,4,7</a>]. Approximately 10 to 15 percent of patients with the indeterminate form develop gastrointestinal disease (within the Southern Cone, where the prevalence of gastrointestinal disease is highest), and a subset of patients develop both cardiac and gastrointestinal (cardiodigestive) disease [<a href="#rid7">7</a>]. </p><p>A retrospective cohort study provided some data on the transition from the indeterminate form (asymptomatic <em>T.</em> <em>cruzi</em> positivity) to chronic Chagas cardiomyopathy (CCC); however, the initial cohort was not limited to the indeterminate form since baseline cardiac testing was not performed. Among 499 initially asymptomatic blood donors in Brazil with <em>T. cruzi</em> seropositivity on initial screening, 24 percent were diagnosed with CCC during mean 10.5 years of follow-up; of these, 26 percent were found to have a left ventricular ejection fraction &lt;50 percent [<a href="#rid9">9</a>]. The estimated progression rate from the indeterminate form to Chagas cardiomyopathy was 1.85 percent per year. Among 488 seronegative donors matched by year of donation, site, age, and sex, 5 percent developed cardiomyopathy during mean 11 years of follow-up. However, the high incidence of Chagas cardiomyopathy in this study may overestimate the risk in individuals with the indeterminate form of Chagas disease; given the lack of baseline cardiac testing, some of the individuals may have had CCC at the outset of the study despite their lack of symptoms. Similarly, a systematic review and meta-analysis of 23 studies of individuals with the indeterminate form reported a pooled annual rate for development of CCC to be 1.9 percent (95% CI 1.3-3.0 percent) after a mean follow-up period of 8.5 years (range 3 to 18 years) [<a href="#rid10">10</a>]. </p><p class="headingAnchor" id="H2096355592"><span class="h2">Determinate forms</span></p><p class="headingAnchor" id="H960078338"><span class="h3">Heart disease</span><span class="headingEndMark"> — </span>Chagas heart disease develops more commonly than gastrointestinal disease. Issues related to Chagas heart disease are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4955.html" rel="external">"Chronic Chagas cardiomyopathy: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4925.html" rel="external">"Chronic Chagas cardiomyopathy: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H1975704446"><span class="h3">Gastrointestinal disease</span><span class="headingEndMark"> — </span>The gastrointestinal form of Chagas disease is rare, especially outside of the Southern Cone countries (Bolivia, Argentina, Paraguay, Uruguay, Chile, Brazil). Issues related to Chagas gastrointestinal disease are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5700.html" rel="external">"Chagas gastrointestinal disease"</a>.)</p><p class="headingAnchor" id="H3679823478"><span class="h2">Reactivation due to immunosuppression</span><span class="headingEndMark"> — </span>Reactivation of chronic <em>T. cruzi</em> infection can occur in patients with immunosuppression due to malignancy, chemotherapy, immunosuppressive regimens for solid organ or bone marrow transplantation, or human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) [<a href="#rid11">11,12</a>]. Clinical findings and management are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/114195.html" rel="external">"Chagas disease in the immunosuppressed host"</a>.)</p><p class="headingAnchor" id="H1462222214"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Chronic Chagas disease should be suspected in individuals who have lived in endemic countries of Latin America and those born to women from endemic countries [<a href="#rid13">13</a>]. Most infected individuals are asymptomatic; cardiac or gastrointestinal symptoms in a patient from Latin America should prompt consideration of chronic Chagas disease.</p><p>Groups at highest risk include those who lived in rural areas, especially in houses with adobe walls, thatched roofs, and/or known triatomine infestation. Vector-borne transmission also occurs in the southern United States, but the risk is much lower than in areas of Latin America with domestic triatomine infestation. Infection prevalence is highest in Bolivia, Argentina, Paraguay, and Ecuador, but most infected immigrants in the United States are from El Salvador and Mexico. (See  <a class="medical medical_review" href="/z/d/html/5698.html" rel="external">"Chagas disease: Epidemiology, screening, and prevention"</a>.)</p><p class="headingAnchor" id="H3676202985"><span class="h2">Diagnose chronic infection</span><span class="headingEndMark"> — </span>Diagnosis of chronic Chagas infection requires serologic methods to detect immunoglobulin (Ig)G antibodies to <em>T. cruzi</em>, most commonly enzyme-linked immunosorbent assay (ELISA) and immunofluorescent antibody assay (IFA) [<a href="#rid3">3</a>]. No available assay has sufficient sensitivity and specificity to be used alone; a positive result by a single assay does not constitute a confirmed diagnosis [<a href="#rid14">14</a>]. Two serologic tests based on different antigens (eg, whole-parasite lysate and recombinant antigens) and/or techniques (eg, ELISA and IFA) are used in parallel to increase the accuracy of the diagnosis [<a href="#rid3">3,5,8</a>]. Data suggest that the sensitivity of serologic assays varies by geographic location, possibly due to <em>T. cruzi</em> strain differences and resulting antibody responses [<a href="#rid15">15-17</a>].</p><p>Individuals tested by two serologic assays with discordant results require further testing. In some cases, the infection status remains difficult to resolve even after a third test because there is no absolute gold-standard assay for chronic <em>T. cruzi </em>infection [<a href="#rid18">18</a>]. Assays such as the radioimmune precipitation assay and IgG trypomastigote excreted-secreted antigen immunoblot are promoted as reference tests, but even these do not have optimal sensitivity and specificity and may not be capable of resolving the diagnosis [<a href="#rid19">19,20</a>].</p><p>Options for <em>T. cruzi</em> serologic testing in the United States are relatively limited. Three ELISA kits based on parasite lysate or recombinant antigens (Ortho ELISA, Wiener Chagatest ELISA Recombinante 3.0, Hemagen ELISA) are cleared by the US Food and Drug Administration (FDA) for diagnostic application [<a href="#rid21">21</a>]. Of these three tests, the Ortho and Wiener ELISAs demonstrated high sensitivity and specificity in published evaluations [<a href="#rid22">22,23</a>]. A rapid test based on recombinant antigens (InBios ChagasDetectPlus) was also cleared by the FDA and could facilitate screening of high-risk populations [<a href="#rid24">24,25</a>]. Use of an assay with validation data (eg, a commercial kit shown to have acceptable sensitivity and specificity in a thorough study) is preferable to reliance on in-house tests for which no performance data are publicly available.</p><p>In general, polymerase chain reaction (PCR) is not a useful diagnostic test for chronic <em>T. cruzi</em> infection. The sensitivity is variable and depends on patient characteristics, sample volume, and PCR primers and methods [<a href="#rid26">26,27</a>]. In the BENEFIT trial (nearly 2900 patients with proven chronic Chagas cardiomyopathy (CCC) and two positive serologic tests with two different techniques), the overall rate of serum PCR positivity was approximately 60 percent [<a href="#rid28">28</a>]. However, quantitative PCR performed under rigorously standardized protocols is increasingly used as a timely indicator of treatment failure in new drug trials. (See <a class="local">'Assessing response to treatment'</a> below.)</p><p>Direct demonstration of parasite by hemoculture or xenodiagnosis in a reliable laboratory indicates true infection, but the techniques are laborious, their sensitivity in the chronic phase is generally less than 50 percent, and final results may not be available for one to two months [<a href="#rid29">29</a>]. Xenodiagnosis consists of feeding laboratory-reared uninfected triatomine bugs directly on the patient or on blood in a membrane-feeding device.</p><p>The United States Centers for Disease Control and Prevention provides consultation to health care providers concerning Chagas disease diagnostic testing and acts as a reference laboratory for Chagas disease serology and PCR (Division of Parasitic Diseases Public Inquiries line, 404-718-4745; for emergencies after business hours, 770-488-7100; email <a class="__cf_email__" data-cfemail="b9c9d8cbd8cad0cddccaf9daddda97ded6cf" href="/cdn-cgi/l/email-protection">[email protected]</a>).</p><p>Issues related to monitoring after transplantation in a patient with chronic <em>T. cruzi</em> infection are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/114195.html" rel="external">"Chagas disease in the immunosuppressed host"</a>.)</p><p class="headingAnchor" id="H708763391"><span class="h2">Identify organ involvement</span><span class="headingEndMark"> — </span>After the diagnosis of chronic <em>T. cruzi</em> infection is established by serologic testing, further evaluation should be pursued to determine whether the patient has evidence of chronic Chagas heart disease or gastrointestinal disease (determinate form) or lacks organ involvement (indeterminate form). </p><p>The initial evaluation includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Medical history, including a review of systems with an emphasis on symptoms suggestive of cardiac arrhythmia (eg, palpitations, atypical angina), early heart failure, thromboembolism, and gastrointestinal disease [<a href="#rid8">8,30,31</a>]. Social history should include details related to potential exposure to the parasite in endemic areas or via blood transfusion or other routes. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete physical examination, chest radiograph, and resting 12-lead electrocardiogram (ECG) with a 30-second lead II rhythm strip [<a href="#rid1">1,3,8,32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with symptoms consistent with gastrointestinal Chagas disease should undergo <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">barium</a> studies and other evaluation as indicated; such testing is not warranted in the absence of symptoms [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/5700.html" rel="external">"Chagas gastrointestinal disease"</a>.)</p><p></p><p class="headingAnchor" id="H3772950014"><span class="h3">Criteria</span><span class="headingEndMark"> — </span>The approach to identification of determinate forms of Chagas disease is controversial. The 2011 Latin American guidelines and the 2015 Second Brazilian consensus on Chagas disease endorsed the classical approach (which does not include echocardiography) [<a href="#rid2">2,4</a>]. In contrast, some experts diagnose the indeterminate form only in patients who lack all the classical criteria for cardiac or gastrointestinal involvement <strong>and</strong> also lack echocardiographic wall motion abnormalities. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classical criteria </strong>—<strong> </strong>The indeterminate (or latent) form of Chagas disease is classically diagnosed in patients with serologic and/or parasitologic evidence of chronic <em>T. cruzi</em> infection who lack <strong>all</strong> of the following: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Symptoms or physical signs of heart failure, arrhythmia, or thromboembolism</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abnormalities on 12-lead-ECG with 30-second lead II rhythm strip [<a href="#rid3">3,8,32</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Any radiographic evidence (on chest radiograph or barium-contrast esophageal or colon radiographs) of cardiac or gastrointestinal involvement [<a href="#rid1">1,4,33,34</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Echocardiography</strong> — In addition to the above classical criteria for indeterminate form, some experts use echocardiography to identify patients with left ventricular (LV) regional or global wall motion abnormalities and exclude patients with these abnormalities from the indeterminate form [<a href="#rid1">1,35</a>]. </p><p></p><p class="headingAnchor" id="H2782368329"><span class="h3">Rationale for echocardiography</span><span class="headingEndMark"> — </span>The rationale for including echocardiography in the evaluation of patients with chronic Chagas disease is that LV wall motion abnormalities have prognostic significance and can occur in the absence of symptoms, ECG alterations, or chest radiograph findings. Several analyses have suggested that early echocardiographic findings such as segmental wall motion abnormalities may indicate the onset of cardiomyopathy even before changes are detected on the ECG [<a href="#rid36">36-38</a>]. The presence of even minor segmental LV systolic abnormalities predicts future global LV systolic dysfunction [<a href="#rid37">37</a>]. In one study including more than 1500 patients with CCC, presence of segmental wall motion abnormalities (in spite of normal global LV systolic function) was predictive of subsequent adverse clinical outcome [<a href="#rid38">38</a>]. In addition, overt CCC may first manifest as stroke or cardiac arrhythmias including sudden cardiac arrest; many patients with these complications have only regional LV systolic dysfunction [<a href="#rid39">39,40</a>]. </p><p>Given the clinical significance of LV wall motion abnormality (focal or global), this finding has the following implications for evaluation and management: </p><p class="bulletIndent1"><span class="glyph">●</span>Patients with LV wall motion abnormality should undergo further evaluation including ambulatory ECG (Holter) monitoring for arrhythmias as well as more intensive follow-up than a patient with the indeterminate form. (See  <a class="medical medical_review" href="/z/d/html/4955.html" rel="external">"Chronic Chagas cardiomyopathy: Clinical manifestations and diagnosis", section on 'Approach to diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/4925.html" rel="external">"Chronic Chagas cardiomyopathy: Management and prognosis", section on 'Monitoring for disease progression'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of any degree of LV systolic dysfunction or an apical aneurysm is a risk factor for cardioembolism and should be considered in assessing the benefits and risks of antithrombotic prophylaxis. (See  <a class="medical medical_review" href="/z/d/html/4925.html" rel="external">"Chronic Chagas cardiomyopathy: Management and prognosis", section on 'Thromboembolism prophylaxis'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with asymptomatic left ventricular systolic dysfunction with left ventricular ejection fraction ≤40 percent should be treated with pharmacologic therapy to reduce the risk of progressive adverse remodeling and development of heart failure. (See  <a class="medical medical_review" href="/z/d/html/4925.html" rel="external">"Chronic Chagas cardiomyopathy: Management and prognosis", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/3509.html" rel="external">"Management and prognosis of asymptomatic left ventricular systolic dysfunction"</a>.) </p><p></p><p class="headingAnchor" id="H1688870739"><span class="h3">Excluded tests</span><span class="headingEndMark"> — </span>In patients with the indeterminate form, we do not use additional testing (beyond ECG, chest radiography, and echocardiography) for evaluation of cardiac disease. While additional tests (such as ambulatory ECG [Holter] monitoring, stress testing, radionuclide ventriculography, cardiovascular magnetic resonance imaging, autonomic evaluation, electrophysiologic testing, cardiac catheterization, and endomyocardial biopsy) may demonstrate significant abnormalities in some patients considered to have the indeterminate form [<a href="#rid4">4,8,35,41,42</a>], data are lacking to support such testing. Abnormalities detected with these tests in individuals fulfilling the other criteria for the indeterminate form have not been demonstrated to have prognostic meaning. Moreover, some longitudinal studies show that as long as the ECG remains normal, infected individuals have the same life expectancy as noninfected controls [<a href="#rid7">7</a>]. </p><p>Parasympathetic autonomic dysfunction (including decreased respiratory heart rate changes and blunted heart rate responses to orthostatic changes) may be detected on specific testing in infected individuals with no signs of cardiomyopathy or digestive Chagas disease [<a href="#rid41">41</a>]. One study including more than 500 individuals with <em>T. cruzi </em>noted presence of subclinical peripheral neuropathy (manifested as decreased tendon reflexes and/or sensory impairment) in 10 percent of cases; there was no reported association with cardiomyopathy or gastrointestinal Chagas disease [<a href="#rid43">43</a>].</p><p>The role of additional testing in patients diagnosed with CCC is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4955.html" rel="external">"Chronic Chagas cardiomyopathy: Clinical manifestations and diagnosis"</a>.) </p><p class="headingAnchor" id="H4204186257"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis for positive <em>T. cruzi</em> serology includes cross reactivity with other antigens (eg, <em>Leishmania</em> species) [<a href="#rid44">44,45</a>]. For this reason, two serologic tests (based on different antigens and/or techniques) are used to reduce the risk of false positive results. (See <a class="local">'Diagnose chronic infection'</a> above.)</p><p>The differential diagnosis of the determinate forms of chronic Chagas disease, including cardiomyopathy and gastrointestinal disease, is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/4955.html" rel="external">"Chronic Chagas cardiomyopathy: Clinical manifestations and diagnosis", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/5700.html" rel="external">"Chagas gastrointestinal disease", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H1718466440"><span class="h1">MANAGEMENT OF INDETERMINATE FORM</span><span class="headingEndMark"> — </span>The approach to management of Chagas disease varies by patient characteristics and phase and form of disease. Management of immunocompetent patients with the indeterminate form of chronic Chagas disease is discussed here. Management of immunosuppressed patients with Chagas disease (including indeterminate form) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/114195.html" rel="external">"Chagas disease in the immunosuppressed host"</a>.)</p><p>Management of patients with determinate forms of chronic Chagas disease is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4925.html" rel="external">"Chronic Chagas cardiomyopathy: Management and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/5700.html" rel="external">"Chagas gastrointestinal disease"</a>.)</p><p class="headingAnchor" id="H745613471"><span class="h2">Antitrypanosomal therapy</span></p><p class="headingAnchor" id="H1431783471"><span class="h3">Indications and rationale for therapy</span><span class="headingEndMark"> — </span>For most patients with the indeterminate form of chronic <em>T. cruzi</em> infection (including children and adults), we suggest antitrypanosomal treatment. For older adults (eg, &gt;50 years), treatment should be considered on a case-by-case basis as comorbidities may decrease tolerance of the prolonged drug course [<a href="#rid2">2,8</a>]. This approach differs from major society guidelines which include a strong recommendation for antitrypanosomal treatment in children and a weak recommendation in adults [<a href="#rid2">2,3,5,7,8</a>]. As discussed below, given that available evidence reflects a surrogate outcome (eg, seroconversion rates), rather than patient-related outcomes, the quality of this evidence is low and thus supports a weak recommendation for children as well as adults. (See  <a class="medical medical_review" href="/z/d/html/14004.html" rel="external">"Chagas disease: Antitrypanosomal drug therapy"</a>.)</p><p>For women who wish to become pregnant, treatment prior to conception is particularly important since observational data suggest that treatment likely reduces the probability of congenital transmission [<a href="#rid5">5,46,47</a>]. Antitrypanosomal drugs are contraindicated during pregnancy, so effective contraception should be assured while on treatment. Additional contraindications to antitrypanosomal drugs include severe renal or hepatic dysfunction. (See  <a class="medical medical_review" href="/z/d/html/14004.html" rel="external">"Chagas disease: Antitrypanosomal drug therapy"</a>.)</p><p>Evidence supporting the use of antitrypanosomal agents for treatment of patients with the indeterminate form of chronic Chagas disease comes from randomized and nonrandomized clinical trials in children and adults [<a href="#rid48">48-52</a>]. Most of the available clinical trials found that treatment increases the likelihood of becoming seronegative, but there are only limited data on the effect of treatment on progression to cardiomyopathy, in part because of the difficulty of achieving the decades of follow-up necessary.</p><p>In one trial including more than 100 children randomly assigned to a 60-day treatment course with <a class="drug drug_general" data-topicid="114673" href="/z/d/drug information/114673.html" rel="external">benznidazole</a> or placebo, 62 percent of patients in the treatment arm were seronegative at four years (compared with none in the placebo arm) [<a href="#rid49">49</a>]. The incidence of new ECG abnormalities was similar in both groups (2.5 and 2.4 percent, respectively), limiting the ability to draw any conclusions about the efficacy of benznidazole in preventing onset of cardiomyopathy. An earlier trial had similar findings, reporting 58 percent seronegativity at three years in the benznidazole arm compared with 5 percent in the placebo arm [<a href="#rid48">48</a>]. The frequency of new ECG abnormalities or incident cardiomyopathy was not reported in this trial.</p><p>In another trial, 120 adults were randomly assigned to one of four 60-day treatment arms (<a class="drug drug_general" data-topicid="114673" href="/z/d/drug information/114673.html" rel="external">benznidazole</a> monotherapy, benznidazole plus <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>, posaconazole monotherapy, or placebo) [<a href="#rid53">53</a>]. At one year, 96 percent of patients treated with benznidazole had negative parasitemia status (measured by polymerase chain reaction [PCR]) compared with 17 percent in the placebo arm (the efficacy of posaconazole was similar to that of placebo). The effect of benznidazole on progression to cardiomyopathy or development of ECG abnormalities was not reported. In an earlier nonrandomized prospective study involving more than 560 adults (ages 30 to 50 years) assigned in alternating sequence to either 30 days of treatment with benznidazole or no treatment, those who received benznidazole had reduced risk of disease progression (4 versus 14 percent; hazard ratio [HR] 0.24, 95% CI 0.10-0.59) and onset of new ECG abnormalities (5 versus 16 percent; HR 0.27, 95% CI 0.13-0.57) [<a href="#rid54">54</a>]. Treated patients more frequently converted to negative serology (15 versus 6 percent; HR 2.1, 95% CI 1.06-4.06). Mortality was lower in the benznidazole group, but the finding was not statistically significant (1.2 versus 4.2 percent; HR 0.2, 95% CI 0.03-1.2). Limitations of this study include its nonrandomized design and the relatively large number of patients lost to follow-up (20 percent of patients in both arms).</p><p>A major barrier to clinical trials in adults is the lack of a true test of cure and the fact that reversion to negative serology in cured patients takes many decades in those treated as adults [<a href="#rid18">18,46,55</a>]. Nevertheless, data from clinical trials indicate that 85 to 95 percent of adult patients who complete a course of <a class="drug drug_general" data-topicid="114673" href="/z/d/drug information/114673.html" rel="external">benznidazole</a> have sustained negative parasitologic tests at 12 months post-treatment based on rigorously standardized quantitative PCR assays [<a href="#rid53">53,56</a>]</p><p class="headingAnchor" id="H2162807376"><span class="h3">Regimen selection</span><span class="headingEndMark"> — </span>Antitrypanosomal drugs include <a class="drug drug_general" data-topicid="114673" href="/z/d/drug information/114673.html" rel="external">benznidazole</a> and <a class="drug drug_general" data-topicid="126252" href="/z/d/drug information/126252.html" rel="external">nifurtimox</a>; in general, benznidazole is favored as the first-line treatment because it is better tolerated. There are also more contemporary data and clinical experience with benznidazole. Dosing and adverse effects are outlined in the tables  (<a class="graphic graphic_table graphicRef54443" href="/z/d/graphic/54443.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef67193" href="/z/d/graphic/67193.html" rel="external">table 2</a>). Issues related to antitrypanosomal drugs are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/14004.html" rel="external">"Chagas disease: Antitrypanosomal drug therapy"</a>.)</p><p><a class="drug drug_general" data-topicid="114673" href="/z/d/drug information/114673.html" rel="external">Benznidazole</a> is typically given for 60 days for chronic indeterminate Chagas disease; most trials and studies have evaluated this duration of treatment (see <a class="local">'Indications and rationale for therapy'</a> above). Although further confirmatory data are needed, emerging evidence suggests that shorter courses (and in some cases, lower doses) may achieve similar treatment outcomes and reduce the severity of side effects. In a phase II, multicenter, randomized controlled trial of 210 adults with chronic indeterminate Chagas disease, high rates of sustained parasitologic response (persistently negative blood PCR at six months) were achieved when benznidazole was given at 300 mg daily for eight weeks (89 percent of 28 individuals), four weeks (89 percent of 28 individuals), two weeks (83 percent of 29 individuals), or at 150 mg daily for four weeks (83 percent of 30 individuals) [<a href="#rid57">57</a>]. Overall, severe adverse events were uncommon, but there were trends towards fewer events in the shorter-duration and lower-dose groups. If these results are confirmed in larger phase III trials, shorter- and/or lower-dose treatment regimens may be recommended in the future.  </p><p class="headingAnchor" id="H1597284281"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>Side effects are fairly common with antitrypanosomal agents. In the available clinical trials, approximately 20 percent of patients discontinued treatment because of adverse effects, most commonly cutaneous and gastrointestinal reactions [<a href="#rid50">50</a>]. Side effects are more common in adults than children and in women than men [<a href="#rid58">58</a>]. Adverse effects of antitrypanosomal drugs are summarized in the table and are discussed in greater detail separately  (<a class="graphic graphic_table graphicRef67193" href="/z/d/graphic/67193.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/14004.html" rel="external">"Chagas disease: Antitrypanosomal drug therapy"</a>.)</p><p>Antitrypanosomal agents are contraindicated in pregnancy and in patients with severe renal or hepatic dysfunction.</p><p class="headingAnchor" id="H2413657394"><span class="h3">Assessing response to treatment</span><span class="headingEndMark"> — </span>There is no sensitive, timely assay for monitoring response to treatment in patients with chronic <em>T. cruzi</em> infection [<a href="#rid8">8</a>]. The length of time required to achieve sustained negative serologic test results following treatment is proportional to the duration of infection; because most individuals who grew up in an area with endemic vector-borne transmission become infected as children, patient age is often used a proxy for the presumed duration of infection. As an example, among females treated by age 15 years, the median time to negative serology in one study was 15 years, whereas among women treated after age 15 years, the median time to negative serology was 27 years [<a href="#rid46">46</a>]. The two randomized trials of <a class="drug drug_general" data-topicid="114673" href="/z/d/drug information/114673.html" rel="external">benznidazole</a> in children used experimental assays measuring lytic antibodies to demonstrate response at three to four years post-treatment, but these assays are not available outside a few research settings [<a href="#rid48">48,49</a>]. Evaluation of other diagnostic tools is ongoing [<a href="#rid59">59</a>]. Thus, there is no practical method to prove treatment success in the chronic phase, and serologic monitoring post-treatment is usually not recommended for those treated in the chronic phase [<a href="#rid8">8</a>].</p><p>In trials of <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> and the ravuconazole pro-drug E1224, the main outcome was parasite detection by carefully standardized real-time PCR in multiple specimens [<a href="#rid60">60-62</a>]. Positive PCR results during post-treatment follow-up provided an early indicator of treatment failure for the experimental arms in these trials. However, negative PCR does not provide proof of cure, and molecular methods are not appropriate for routine clinical use to monitor response to treatment in patients with chronic <em>T. cruzi</em> infection.</p><p class="headingAnchor" id="H785392402"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Patients with the indeterminate form should be monitored for development of cardiac or gastrointestinal dysfunction.</p><p class="headingAnchor" id="H3914254461"><span class="h3">Cardiac involvement</span><span class="headingEndMark"> — </span>For patients with the indeterminate form, the optimal approach to monitoring for development of left ventricular dysfunction is uncertain. We suggest the following approach:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients should undergo annual history and physical examination and ECG to monitor for new abnormalities that may herald development of Chagas cardiomyopathy or gastrointestinal disease [<a href="#rid1">1,3,8</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The development of symptoms or signs of heart failure, thromboembolic disease or arrhythmia should prompt further cardiac evaluation including ambulatory ECG (Holter) monitoring. Diagnosis and management of chronic Chagas cardiomyopathy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4955.html" rel="external">"Chronic Chagas cardiomyopathy: Clinical manifestations and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/4925.html" rel="external">"Chronic Chagas cardiomyopathy: Management and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest echocardiographic assessment at regular intervals (eg, every three to five years) [<a href="#rid35">35</a>], given the importance of identifying even minor wall motion abnormalities. (See <a class="local">'Rationale for echocardiography'</a> above and  <a class="medical medical_review" href="/z/d/html/4955.html" rel="external">"Chronic Chagas cardiomyopathy: Clinical manifestations and diagnosis"</a>.) </p><p></p><p class="bulletIndent1">The utility of brain natriuretic peptide (BNP) plasma levels as a means of identifying patients who should undergo echocardiography has not been established. In a controlled study of 151 patients seropositive for Chagas disease (90 percent of whom had a left ventricular ejection fraction &gt;40 percent), among those with an abnormal ECG or chest radiograph, plasma BNP ≥60.7 pmol/L had good sensitivity and specificity for detection of LV dysfunction (80 and 97 percent, respectively) [<a href="#rid63">63</a>]. Further studies are needed to determine the utility and cost-effectiveness of this approach prior to implementation in endemic areas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If echocardiography is not available, we suggest repeating a chest radiograph every three to five years. </p><p></p><p class="headingAnchor" id="H2493520872"><span class="h3">Gastrointestinal involvement</span><span class="headingEndMark"> — </span>For patients with the indeterminate form, the approach to monitoring for development of gastrointestinal involvement depends on the prevalence of digestive involvement in the country of origin. Asymptomatic patients should be reassessed annually for gastrointestinal symptoms. In patients from countries where the gastrointestinal form occurs most frequently (mainly the Southern Cone of South America), radiographic evaluation for gastrointestinal involvement using <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">barium</a> esophagram and colon enema may be appropriate. The presence of gastrointestinal tract symptoms (eg, dysphagia, constipation) should prompt evaluation with barium contrast studies. Diagnosis and management of Chagas gastrointestinal disease is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5700.html" rel="external">"Chagas gastrointestinal disease"</a>.)</p><p class="headingAnchor" id="H3478774651"><span class="h2">Family screening and patient counseling</span><span class="headingEndMark"> — </span>Diagnostic screening should be offered for family members with a similar history of potential exposure to the parasite in endemic settings and for all children of infected women [<a href="#rid8">8</a>]. In one study including 86 <em>T. cruzi</em>-infected individuals in Los Angeles, 189 family members underwent screening; 7.4 percent of these individuals were seropositive. The mean age of infected relatives was 48 years; the mean age of uninfected relatives was 24 years [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/z/d/html/7950.html" rel="external">"Blood donor screening: Medical history", section on 'Chagas disease'</a>.)</p><p>Infected individuals should be counseled not to donate blood or organs.</p><p class="headingAnchor" id="H2402391903"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113058.html" rel="external">"Society guideline links: Chagas disease"</a>.)</p><p class="headingAnchor" id="H724873096"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/97518.html" rel="external">"Patient education: Chagas disease (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1285149509"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><em>Trypanosoma cruzi</em> infection is characterized by two phases, acute and chronic. The acute phase of <em>T. cruzi</em> infection lasts 8 to 12 weeks following transmission and is characterized by presence of circulating trypomastigotes. When the host immune response succeeds in decreasing parasite replication, parasitemia falls below levels detectable by microscopy, acute symptoms resolve, and the patient passes into the chronic phase, which lasts for the life of the patient. (See <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nearly all <em>T. cruzi-</em>infected persons have the indeterminate (asymptomatic) form during the first one to three decades of the chronic phase. Patients with the indeterminate form of the chronic phase of <em>T. cruzi</em> infection have positive serology but no signs or symptoms of cardiomyopathy or gastrointestinal disease. Such patients have normal 12-lead electrocardiogram (ECG) findings and normal radiographic examinations of the chest, esophagus, and colon. An estimated 20 to 40 percent subsequently develop clinically evident cardiac and/or gastrointestinal forms of the disease. (See <a class="local">'Indeterminate form'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic Chagas disease should be suspected in individuals who have lived in endemic countries of Latin America and those born to women from endemic countries, especially including those who lived in rural areas in houses with adobe walls, thatched roofs, and/or known triatomine infestation. Most infected individuals are asymptomatic; cardiac or gastrointestinal symptoms in a patient from Latin America should prompt consideration of chronic Chagas disease. Vector-borne transmission also occurs in the southern United States, but the risk is much lower than in areas of Latin America with domestic triatomine infestation. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis of chronic infection requires serologic methods to detect immunoglobulin (Ig)G antibodies to <em>T. cruzi</em>. Two tests based on different antigens and/or techniques are used in parallel to increase the accuracy of the diagnosis; no available assay has sufficient sensitivity and specificity to be used alone. (See <a class="local">'Diagnose chronic infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After the diagnosis of chronic <em>T. cruzi</em> infection is confirmed by serologic testing, the initial evaluation consists of medical history, including a review of systems with an emphasis on symptoms suggestive of cardiac arrhythmia (eg, palpitations, atypical angina), early heart failure, thromboembolism, and gastrointestinal disease. Social history should include details related to potential exposure to the parasite in endemic areas or via blood transfusion or other routes. Clinical evaluation should include complete physical examination and resting 12-lead ECG with a 30-second lead II rhythm strip. (See <a class="local">'Identify organ involvement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The approach to identification of the indeterminate form of Chagas disease is controversial. We diagnose the indeterminate form using classical criteria (exclusion of cardiac symptoms and signs and abnormalities on ECG, chest radiograph, or gastrointestinal radiographs) plus echocardiographic findings. (See <a class="local">'Diagnosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of the indeterminate form of Chagas disease includes antitrypanosomal therapy and monitoring for development of cardiac or gastrointestinal dysfunction. (See <a class="local">'Management of indeterminate form'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The approach to antitrypanosomal therapy for Chagas disease varies by phase and form of disease:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Indeterminate form – For most patients with the indeterminant form of chronic <em>T. cruzi</em> infection, including children and adults, we suggest antitrypanosomal treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Treatment of older adults (eg, &gt;50 years old) should be considered on a case-by-case basis since drug tolerance may be lower. (See <a class="local">'Indications and rationale for therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chagas cardiomyopathy – Antitrypanosomal therapy may be beneficial to patients with early or mild chronic Chagas cardiomyopathy but it does not appear to be beneficial for patients with advanced cardiomyopathy. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4925.html" rel="external">"Chronic Chagas cardiomyopathy: Management and prognosis", section on 'Management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chagas gastrointestinal disease – Management of Chagas gastrointestinal disease focuses on symptom amelioration. Antitrypanosomal therapy generally does not play a role. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5700.html" rel="external">"Chagas gastrointestinal disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reactivation in an immunosuppressed host – Treatment and prevention of <em>T. cruzi</em> reactivation in immunosuppressed patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/114195.html" rel="external">"Chagas disease in the immunosuppressed host"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antitrypanosomal drugs include <a class="drug drug_general" data-topicid="114673" href="/z/d/drug information/114673.html" rel="external">benznidazole</a> and <a class="drug drug_general" data-topicid="126252" href="/z/d/drug information/126252.html" rel="external">nifurtimox</a>. We suggest benznidazole as the first-line treatment for Chagas disease (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The basis for our recommendation is that benznidazole is generally better tolerated, the available data on it are more recent, and there is greater experience using it in the contemporary era. Dosing and adverse effects are outlined in the tables  (<a class="graphic graphic_table graphicRef54443" href="/z/d/graphic/54443.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef67193" href="/z/d/graphic/67193.html" rel="external">table 2</a>). Issues related to antitrypanosomal drugs are discussed further separately. (See <a class="local">'Regimen selection'</a> above and  <a class="medical medical_review" href="/z/d/html/14004.html" rel="external">"Chagas disease: Antitrypanosomal drug therapy"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nunes MCP, Beaton A, Acquatella H, et al. Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association. Circulation 2018; 138:e169.</a></li><li><a class="nounderline abstract_t">Dias JC, Ramos AN Jr, Gontijo ED, et al. 2 nd Brazilian Consensus on Chagas Disease, 2015. Rev Soc Bras Med Trop 2016; 49Suppl 1:3.</a></li><li><a class="nounderline abstract_t">Bern C. Chagas' Disease. N Engl J Med 2015; 373:456.</a></li><li><a class="nounderline abstract_t">Andrade JP, Marin Neto JA, Paola AA, et al. I Latin American Guidelines for the diagnosis and treatment of Chagas' heart disease: executive summary. Arq Bras Cardiol 2011; 96:434.</a></li><li class="breakAll">Pan American Health Organization. Guidelines for the diagnosis and treatment of Chagas disease. Washington, D.C.: PAHO; 2019. http://iris.paho.org/xmlui/bitstream/handle/123456789/49653/9789275120439_eng.pdf?sequence=6&amp;isAllowed=y (Accessed on July 08, 2019).</li><li><a class="nounderline abstract_t">Bern C, Messenger LA, Whitman JD, Maguire JH. Chagas Disease in the United States: a Public Health Approach. Clin Microbiol Rev 2019; 33.</a></li><li><a class="nounderline abstract_t">Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010; 375:1388.</a></li><li><a class="nounderline abstract_t">Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 2007; 298:2171.</a></li><li><a class="nounderline abstract_t">Sabino EC, Ribeiro AL, Salemi VM, et al. Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors. Circulation 2013; 127:1105.</a></li><li><a class="nounderline abstract_t">Chadalawada S, Sillau S, Archuleta S, et al. Risk of Chronic Cardiomyopathy Among Patients With the Acute Phase or Indeterminate Form of Chagas Disease: A Systematic Review and Meta-analysis. JAMA Netw Open 2020; 3:e2015072.</a></li><li><a class="nounderline abstract_t">Bern C. Chagas disease in the immunosuppressed host. Curr Opin Infect Dis 2012; 25:450.</a></li><li><a class="nounderline abstract_t">Martinez-Perez A, Norman FF, Monge-Maillo B, et al. An approach to the management of Trypanosoma cruzi infection (Chagas' disease) in immunocompromised patients. Expert Rev Anti Infect Ther 2014; 12:357.</a></li><li><a class="nounderline abstract_t">Forsyth CJ, Manne-Goehler J, Bern C, et al. Recommendations for Screening and Diagnosis of Chagas Disease in the United States. J Infect Dis 2022; 225:1601.</a></li><li class="breakAll">World Health Organization. Control of Chagas Disease: Second report of the WHO expert committee. WHO, Geneva 2002. http://apps.who.int/iris/bitstream/10665/42443/1/WHO_TRS_905.pdf (Accessed on August 01, 2017).</li><li><a class="nounderline abstract_t">Sosa-Estani S, Gamboa-León MR, Del Cid-Lemus J, et al. Use of a rapid test on umbilical cord blood to screen for Trypanosoma cruzi infection in pregnant women in Argentina, Bolivia, Honduras, and Mexico. Am J Trop Med Hyg 2008; 79:755.</a></li><li><a class="nounderline abstract_t">Umezawa ES, Bastos SF, Camargo ME, et al. Evaluation of recombinant antigens for serodiagnosis of Chagas' disease in South and Central America. J Clin Microbiol 1999; 37:1554.</a></li><li><a class="nounderline abstract_t">Verani JR, Seitz A, Gilman RH, et al. Geographic variation in the sensitivity of recombinant antigen-based rapid tests for chronic Trypanosoma cruzi infection. Am J Trop Med Hyg 2009; 80:410.</a></li><li><a class="nounderline abstract_t">Tarleton RL, Reithinger R, Urbina JA, et al. The challenges of Chagas Disease-- grim outlook or glimmer of hope. PLoS Med 2007; 4:e332.</a></li><li><a class="nounderline abstract_t">Leiby DA, Wendel S, Takaoka DT, et al. Serologic testing for Trypanosoma cruzi: comparison of radioimmunoprecipitation assay with commercially available indirect immunofluorescence assay, indirect hemagglutination assay, and enzyme-linked immunosorbent assay kits. J Clin Microbiol 2000; 38:639.</a></li><li><a class="nounderline abstract_t">Silveira-Lacerda EP, Silva AG, Junior SF, et al. Chagas' disease: application of TESA-blot in inconclusive sera from a Brazilian blood bank. Vox Sang 2004; 87:204.</a></li><li class="breakAll">Lopez-Velez R, Norman FF, Bern C. American Trypanosomiasis (Chagas Disease). In: Hunter's Tropical Medicine and Emerging Infectious Desease, 9th ed, Magill AJ, Ryan ET, Solomon T, Hill DR (Eds), Saunders, Philadelphia 2013. p.725.</li><li><a class="nounderline abstract_t">Gorlin J, Rossmann S, Robertson G, et al. Evaluation of a new Trypanosoma cruzi antibody assay for blood donor screening. Transfusion 2008; 48:531.</a></li><li><a class="nounderline abstract_t">Ramírez JD, Guhl F, Umezawa ES, et al. Evaluation of adult chronic Chagas' heart disease diagnosis by molecular and serological methods. J Clin Microbiol 2009; 47:3945.</a></li><li class="breakAll">InBios. FDA Clears First Point of Care Rapid Diagnostic Test Kit for Chagas Disease. Seattle, 2016. http://www.prweb.com/releases/2016/12/prweb13938661.htm (Accessed on August 01, 2017).</li><li><a class="nounderline abstract_t">Shah V, Ferrufino L, Gilman RH, et al. Field evaluation of the InBios Chagas detect plus rapid test in serum and whole-blood specimens in Bolivia. Clin Vaccine Immunol 2014; 21:1645.</a></li><li><a class="nounderline abstract_t">Schijman AG, Bisio M, Orellana L, et al. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl Trop Dis 2011; 5:e931.</a></li><li><a class="nounderline abstract_t">Qvarnstrom Y, Schijman AG, Veron V, et al. Sensitive and specific detection of Trypanosoma cruzi DNA in clinical specimens using a multi-target real-time PCR approach. PLoS Negl Trop Dis 2012; 6:e1689.</a></li><li><a class="nounderline abstract_t">Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med 2015; 373:1295.</a></li><li class="breakAll">Williams JE. Leishmania and Trypanosoma. In: Medical Parasitology: A Practical Approach, Gillespie SH, Hawkey PM (Eds), Oxford University Press, Oxford, UK 1995. p.151.</li><li><a class="nounderline abstract_t">Bern C. Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 2011; 364:2527.</a></li><li><a class="nounderline abstract_t">Pérez-Molina JA, Molina I. Chagas disease. Lancet 2018; 391:82.</a></li><li><a class="nounderline abstract_t">Lázzari JO, Pereira M, Antunes CM, et al. Diagnostic electrocardiography in epidemiological studies of Chagas' disease: multicenter evaluation of a standardized method. Rev Panam Salud Publica 1998; 4:317.</a></li><li><a class="nounderline abstract_t">Primeira Reunião de. Validade do conceito de forma indeterminada. Rev Soc Bras Med Trop 1985; 18:46.</a></li><li><a class="nounderline abstract_t">Ribeiro AL, Rocha MO. [Indeterminate form of Chagas disease: considerations about diagnosis and prognosis]. Rev Soc Bras Med Trop 1998; 31:301.</a></li><li><a class="nounderline abstract_t">Marin-Neto JA, Almeida Filho OC, Pazin-Filho A, Maciel BC. [Indeterminate form of Chagas' disease. Proposal of new diagnostic criteria and perspectives for early treatment of cardiomyopathy]. Arq Bras Cardiol 2002; 79:623.</a></li><li><a class="nounderline abstract_t">Acquatella H, Asch FM, Barbosa MM, et al. Recommendations for Multimodality Cardiac Imaging in Patients with Chagas Disease: A Report from the American Society of Echocardiography in Collaboration With the InterAmerican Association of Echocardiography (ECOSIAC) and the Cardiovascular Imaging Department of the Brazilian Society of Cardiology (DIC-SBC). J Am Soc Echocardiogr 2018; 31:3.</a></li><li><a class="nounderline abstract_t">Pazin-Filho A, Romano MM, Almeida-Filho OC, et al. Minor segmental wall motion abnormalities detected in patients with Chagas' disease have adverse prognostic implications. Braz J Med Biol Res 2006; 39:483.</a></li><li><a class="nounderline abstract_t">Schmidt A, Dias Romano MM, Marin-Neto JA, et al. Effects of Trypanocidal Treatment on Echocardiographic Parameters in Chagas Cardiomyopathy and Prognostic Value of Wall Motion Score Index: A BENEFIT Trial Echocardiographic Substudy. J Am Soc Echocardiogr 2019; 32:286.</a></li><li><a class="nounderline abstract_t">Rassi A Jr, Rassi SG, Rassi A. Sudden death in Chagas' disease. Arq Bras Cardiol 2001; 76:75.</a></li><li><a class="nounderline abstract_t">Carod-Artal FJ, Vargas AP, Horan TA, Nunes LG. Chagasic cardiomyopathy is independently associated with ischemic stroke in Chagas disease. Stroke 2005; 36:965.</a></li><li><a class="nounderline abstract_t">Marin-Neto JA, Bromberg-Marin G, Pazin-Filho A, et al. Cardiac autonomic impairment and early myocardial damage involving the right ventricle are independent phenomena in Chagas' disease. Int J Cardiol 1998; 65:261.</a></li><li><a class="nounderline abstract_t">Barretto AC, Ianni BM. The undetermined form of Chagas' heart disease: concept and forensic implications. Sao Paulo Med J 1995; 113:797.</a></li><li><a class="nounderline abstract_t">Genovese O, Ballario C, Storino R, et al. Clinical manifestations of peripheral nervous system involvement in human chronic Chagas disease. Arq Neuropsiquiatr 1996; 54:190.</a></li><li><a class="nounderline abstract_t">Abras A, Gállego M, Llovet T, et al. Serological Diagnosis of Chronic Chagas Disease: Is It Time for a Change? J Clin Microbiol 2016; 54:1566.</a></li><li><a class="nounderline abstract_t">Vega Benedetti AF, Cimino RO, Cajal PS, et al. Performance of different Trypanosoma cruzi antigens in the diagnosis of Chagas disease in patients with American cutaneous leishmaniasis from a co-endemic region in Argentina. Trop Med Int Health 2013; 18:1103.</a></li><li><a class="nounderline abstract_t">Fabbro DL, Danesi E, Olivera V, et al. Trypanocide treatment of women infected with Trypanosoma cruzi and its effect on preventing congenital Chagas. PLoS Negl Trop Dis 2014; 8:e3312.</a></li><li><a class="nounderline abstract_t">Murcia L, Simón M, Carrilero B, et al. Treatment of Infected Women of Childbearing Age Prevents Congenital Trypanosoma cruzi Infection by Eliminating the Parasitemia Detected by PCR. J Infect Dis 2017; 215:1452.</a></li><li><a class="nounderline abstract_t">de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348:1407.</a></li><li><a class="nounderline abstract_t">Sosa Estani S, Segura EL, Ruiz AM, et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 1998; 59:526.</a></li><li><a class="nounderline abstract_t">Pérez-Molina JA, Pérez-Ayala A, Moreno S, et al. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009; 64:1139.</a></li><li><a class="nounderline abstract_t">Reyes PA, Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst Rev 2005; :CD004102.</a></li><li><a class="nounderline abstract_t">Villar JC, Perez JG, Cortes OL, et al. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev 2014; :CD003463.</a></li><li><a class="nounderline abstract_t">Morillo CA, Waskin H, Sosa-Estani S, et al. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial. J Am Coll Cardiol 2017; 69:939.</a></li><li><a class="nounderline abstract_t">Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006; 144:724.</a></li><li><a class="nounderline abstract_t">Pinazo MJ, Thomas MC, Bua J, et al. Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review. Expert Rev Anti Infect Ther 2014; 12:479.</a></li><li><a class="nounderline abstract_t">Molina I, Gómez i Prat J, Salvador F, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med 2014; 370:1899.</a></li><li><a class="nounderline abstract_t">Torrico F, Gascón J, Barreira F, et al. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial. Lancet Infect Dis 2021; 21:1129.</a></li><li><a class="nounderline abstract_t">Crespillo-Andújar C, Venanzi-Rullo E, López-Vélez R, et al. Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis. Drug Saf 2018; 41:1035.</a></li><li><a class="nounderline abstract_t">Jurado Medina L, Chassaing E, Ballering G, et al. Prediction of parasitological cure in children infected with Trypanosoma cruzi using a novel multiplex serological approach: an observational, retrospective cohort study. Lancet Infect Dis 2021; 21:1141.</a></li><li><a class="nounderline abstract_t">Molina I, Salvador F, Sánchez-Montalvá A. Posaconazole versus benznidazole for chronic Chagas' disease. N Engl J Med 2014; 371:966.</a></li><li><a class="nounderline abstract_t">Ramírez JC, Cura CI, da Cruz Moreira O, et al. Analytical Validation of Quantitative Real-Time PCR Methods for Quantification of Trypanosoma cruzi DNA in Blood Samples from Chagas Disease Patients. J Mol Diagn 2015; 17:605.</a></li><li><a class="nounderline abstract_t">Chatelain E. Chagas disease drug discovery: toward a new era. J Biomol Screen 2015; 20:22.</a></li><li><a class="nounderline abstract_t">Ribeiro AL, dos Reis AM, Barros MV, et al. Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease. Lancet 2002; 360:461.</a></li><li><a class="nounderline abstract_t">Hernandez S, Forsyth CJ, Flores CA, Meymandi SK. Prevalence of Chagas Disease Among Family Members of Previously Diagnosed Patients in Los Angeles, California. Clin Infect Dis 2019; 69:1226.</a></li></ol></div><div id="topicVersionRevision">Topic 114192 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30354432" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27982292" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2 nd Brazilian Consensus on Chagas Disease, 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26222561" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Chagas' Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21789345" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : I Latin American Guidelines for the diagnosis and treatment of Chagas' heart disease: executive summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21789345" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : I Latin American Guidelines for the diagnosis and treatment of Chagas' heart disease: executive summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31776135" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Chagas Disease in the United States: a Public Health Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20399979" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Chagas disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18000201" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Evaluation and treatment of chagas disease in the United States: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23393012" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32865573" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk of Chronic Cardiomyopathy Among Patients With the Acute Phase or Indeterminate Form of Chagas Disease: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22614520" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Chagas disease in the immunosuppressed host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24484076" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : An approach to the management of Trypanosoma cruzi infection (Chagas' disease) in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34623435" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Recommendations for Screening and Diagnosis of Chagas Disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34623435" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Recommendations for Screening and Diagnosis of Chagas Disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18981518" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Use of a rapid test on umbilical cord blood to screen for Trypanosoma cruzi infection in pregnant women in Argentina, Bolivia, Honduras, and Mexico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10203520" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Evaluation of recombinant antigens for serodiagnosis of Chagas' disease in South and Central America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19270291" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Geographic variation in the sensitivity of recombinant antigen-based rapid tests for chronic Trypanosoma cruzi infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18162039" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The challenges of Chagas Disease-- grim outlook or glimmer of hope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10655360" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Serologic testing for Trypanosoma cruzi: comparison of radioimmunoprecipitation assay with commercially available indirect immunofluorescence assay, indirect hemagglutination assay, and enzyme-linked immunosorbent assay kits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15569074" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Chagas' disease: application of TESA-blot in inconclusive sera from a Brazilian blood bank.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15569074" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Chagas' disease: application of TESA-blot in inconclusive sera from a Brazilian blood bank.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18067497" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evaluation of a new Trypanosoma cruzi antibody assay for blood donor screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19846646" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evaluation of adult chronic Chagas' heart disease diagnosis by molecular and serological methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19846646" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Evaluation of adult chronic Chagas' heart disease diagnosis by molecular and serological methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25274804" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Field evaluation of the InBios Chagas detect plus rapid test in serum and whole-blood specimens in Bolivia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21264349" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22802973" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Sensitive and specific detection of Trypanosoma cruzi DNA in clinical specimens using a multi-target real-time PCR approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26323937" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26323937" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21714649" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Antitrypanosomal therapy for chronic Chagas' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28673423" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Chagas disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9883073" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Diagnostic electrocardiography in epidemiological studies of Chagas' disease: multicenter evaluation of a standardized method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Validade do conceito de forma indeterminada</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9612022" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : [Indeterminate form of Chagas disease: considerations about diagnosis and prognosis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12532246" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : [Indeterminate form of Chagas' disease. Proposal of new diagnostic criteria and perspectives for early treatment of cardiomyopathy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29306364" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Recommendations for Multimodality Cardiac Imaging in Patients with Chagas Disease: A Report from the American Society of Echocardiography in Collaboration With the InterAmerican Association of Echocardiography (ECOSIAC) and the Cardiovascular Imaging Department of the Brazilian Society of Cardiology (DIC-SBC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16612471" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Minor segmental wall motion abnormalities detected in patients with Chagas' disease have adverse prognostic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30420161" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effects of Trypanocidal Treatment on Echocardiographic Parameters in Chagas Cardiomyopathy and Prognostic Value of Wall Motion Score Index: A BENEFIT Trial Echocardiographic Substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11175486" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sudden death in Chagas' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15845889" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Chagasic cardiomyopathy is independently associated with ischemic stroke in Chagas disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9740483" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cardiac autonomic impairment and early myocardial damage involving the right ventricle are independent phenomena in Chagas' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8650479" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The undetermined form of Chagas' heart disease: concept and forensic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8984973" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical manifestations of peripheral nervous system involvement in human chronic Chagas disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27053668" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Serological Diagnosis of Chronic Chagas Disease: Is It Time for a Change?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23837449" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Performance of different Trypanosoma cruzi antigens in the diagnosis of Chagas disease in patients with American cutaneous leishmaniasis from a co-endemic region in Argentina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25411847" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Trypanocide treatment of women infected with Trypanosoma cruzi and its effect on preventing congenital Chagas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28201741" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Treatment of Infected Women of Childbearing Age Prevents Congenital Trypanosoma cruzi Infection by Eliminating the Parasitemia Detected by PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8937280" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9790423" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19819909" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16235350" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24867876" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28231946" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16702588" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24621252" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24827034" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33836161" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30006773" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33836157" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prediction of parasitological cure in children infected with Trypanosoma cruzi using a novel multiplex serological approach: an observational, retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25184871" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Posaconazole versus benznidazole for chronic Chagas' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320872" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Analytical Validation of Quantitative Real-Time PCR Methods for Quantification of Trypanosoma cruzi DNA in Blood Samples from Chagas Disease Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25245987" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Chagas disease drug discovery: toward a new era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12241721" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31220221" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Prevalence of Chagas Disease Among Family Members of Previously Diagnosed Patients in Los Angeles, California.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
